Moderna-Merck's mRNA cancer vaccine shows promise; why some blood stem cells go rogue

Hematologists may have one of their first windows into how to prevent the mutations that prompt blood stem cells to progress into cancer.

April 18, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | Moderna-Merck mRNA cancer vaccine shows promise in combination with melanoma drug A new study provides the strongest evidence yet that a personalized cancer vaccine can offer clinical benefit to patients. By Angus Chen STAT+ | Why do some blood stem cells go rogue? Study offers clue and possible target Many people have blood cell clones that have the potential to turn cancerous. A specific DNA change is now identified as a key. By Angus Chen STAT+ | Most large U.S. funders of clinical research have poor transparency policies, analysis finds Most organizations failed to adopt best disclosure practices recommended by the World Health Organization, the analysis found. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser